Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,935

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin

Open access
Pertwee, R G·2008·British Journal of Pharmacology
DOI 10.1038/sj.bjp.0707442
Open this paper in CoChat — free account

Abstract

Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review focuses on the manner with which three of these compounds, (−)‐trans‐Δ 9‐tetrahydrocannabinol (Δ 9‐THC), (−)‐cannabidiol (CBD) and (−)‐trans‐Δ 9‐tetrahydrocannabivarin (Δ 9‐THCV), interact with cannabinoid CB 1 and CB 2 receptors. Δ 9‐THC, the main psychotropic constituent of cannabis, is a CB 1 and CB 2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by the expression level and signalling efficiency of cannabinoid receptors and by ongoing endogenous cannabinoid release. CBD displays unexpectedly high potency as an antagonist of CB 1/CB 2 receptor agonists in CB 1‐ and CB 2‐expressing cells or tissues, the manner with which it interacts with CB 2 receptors providing a possible explanation for its ability to inhibit evoked immune cell migration. Δ 9‐THCV behaves as a potent CB 2 receptor partial agonist in vitro. In contrast, it antagonizes cannabinoid receptor agonists in CB 1‐expressing tissues. This it does with relatively high potency and in a manner that is both tissue and ligand dependent. Δ 9‐THCV also interacts with CB 1 receptors when administered in vivo, behaving either as a CB 1 antagonist or, at higher doses, as a CB 1 receptor agonist. Brief mention is also made in this review, first of the production by Δ 9‐THC of pharmacodynamic tolerance, second of current knowledge about the extent to which Δ 9‐THC, CBD and Δ 9‐THCV interact with pharmacological targets other than CB 1 or CB 2 receptors, and third of actual and potential therapeutic applications for each of these cannabinoids. British Journal of Pharmacology(2008)153, 199–215; doi:10.1038/sj.bjp.0707442; published online 10 September 2007

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707442

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 170

  1. 10.1074/jbc.M608900200 · DOI
  2. 10.1016/j.pain.2006.04.001 · DOI
  3. 10.1038/sj.bjp.0704829 · DOI
  4. 10.1074/jbc.271.17.9902 · DOI
  5. 10.1007/s00213-002-1144-9 · DOI
  6. 10.1002/syn.1075 · DOI
  7. Bifulco M, 2007, Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review), Oncol Rep, 17, 813
  8. 10.1038/sj.bjp.0704327 · DOI · Paper page
  9. 10.1096/fj.06-6638fje · DOI · Paper page
  10. 10.1016/j.ejphar.2004.10.043 · DOI
  11. 10.1016/j.ejphar.2006.10.038 · DOI
  12. 10.1046/j.1471-4159.1999.0732447.x · DOI · Paper page
  13. 10.1124/mol.60.1.155 · DOI · Paper page
  14. 10.1002/bms.1200150708 · DOI
  15. 10.1021/jm950934b · DOI
  16. Cabral GA, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 385
  17. 10.1016/j.brainres.2006.06.001 · DOI
  18. 10.1158/0008-5472.CAN-06-0169 · DOI · Paper page
  19. Cawthorne MA, 2007, Symposium on the Cannabinoids
  20. 10.1016/S0028-3908(98)00208-1 · DOI
  21. 10.1208/aapsj080113 · DOI
  22. 10.1111/j.1528-1157.1979.tb04816.x · DOI
  23. 10.1016/S0006-8993(01)02825-6 · DOI
  24. 10.1016/0091-3057(82)90418-X · DOI
  25. 10.1016/j.pbb.2004.10.019 · DOI
  26. 10.1016/j.ejphar.2004.02.018 · DOI
  27. 10.1097/00008877-200402000-00001 · DOI
  28. DennisI WhalleyB StephensG(2007).Effects of cannabinoids on [35S]GTPγS binding in specific regions of the mouse brain. Poster P041 at theJoint Focused Meeting/3rd European Workshop on Cannabinoid Research University of Nottingham UK 20 and 21 April 2007. Focused Meeting of the British Pharmacological Society.
  29. 10.1126/science.1470919 · DOI · Paper page
  30. Dewey WL, 1986, Cannabinoid pharmacology, Pharmacol Rev, 38, 151
  31. 10.1046/j.1471-4159.2000.0752434.x · DOI · Paper page
  32. Di Marzo V, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 147
  33. 10.1016/j.neuropharm.2005.11.008 · DOI
  34. Felder CC, 1995, Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors, Mol Pharmacol, 48, 443
  35. 10.1007/BF01065669 · DOI
  36. 10.1517/13543784.14.6.695 · DOI
  37. Gauson LA, 2007, Symposium on the Cannabinoids
  38. 10.1038/228134a0 · DOI
  39. 10.1016/j.brainres.2005.11.035 · DOI · Paper page
  40. 10.1111/j.1749-6632.1999.tb09356.x · doi:10.1111/j.1749-6632.1999.tb09356.x
  41. 10.1038/nrc1188 · DOI · Paper page
  42. Guzmán M, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 627
  43. 10.1038/sj.bjc.6603236 · DOI · Paper page
  44. 10.1016/S0028-3908(02)00157-0 · DOI
  45. 10.1111/j.1460-9568.2007.05476.x · DOI
  46. 10.1016/j.ejphar.2006.07.024 · DOI
  47. 10.1124/mol.105.019174 · DOI
  48. 10.1016/j.yexcr.2006.03.009 · DOI
  49. 10.1159/000136462 · DOI
  50. 10.1124/pr.54.2.161 · DOI · Paper page
  51. 10.1016/S0968-0896(99)00219-9 · DOI · Paper page
  52. Iwamura H, 2001, In vitro and in vivo pharmacological characterization of JTE‐907, a novel selective ligand for cannabinoid CB2 receptor, J Pharmacol Exp Ther, 296, 420, 10.1016/S0022-3565(24)38760-9 · DOI
  53. 10.1016/S0016-5085(03)00892-8 · DOI
  54. Izzo AA, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 573
  55. 10.1038/sj.bjp.0704293 · DOI · Paper page
  56. 10.1097/00008877-200509000-00009 · DOI
  57. 10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.0.CO;2-P · doi:10.1002/1531-8249(200008)48:2<257::aid-ana18>3.0.co;2-p
  58. 10.1016/j.pbb.2005.01.026 · DOI
  59. 10.1007/s00210-006-0033-x · DOI · Paper page
  60. 10.1016/j.neuropharm.2003.11.005 · DOI
  61. 10.1016/j.ejphar.2006.05.025 · DOI
  62. 10.1152/ajpgi.00407.2005 · DOI · Paper page
  63. 10.1093/jb/mvi021 · DOI
  64. 10.1111/j.1471-4159.2006.03873.x · DOI
  65. 10.1016/j.cub.2005.07.005 · DOI
  66. 10.1093/bja/aei098 · DOI
  67. 10.1124/jpet.104.077974 · DOI · Paper page
  68. 10.1172/JCI107431 · doi:10.1172/jci107431
  69. Lichtman AH, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 691
  70. 10.1016/j.physbeh.2006.04.014 · DOI
  71. 10.1124/jpet.105.093500 · DOI
  72. Ma Y‐L, 2006, The phytocannabinoid Δ9‐tetrahydrocannabivarin modulates synaptic transmission at central inhibitory synapses, Proc Br Pharmacol Soc
  73. 10.1038/sj.bjp.0701915 · DOI
  74. MacLennan SJ, 1998, Symposium on the Cannabinoids
  75. 10.1016/j.tins.2006.01.008 · DOI · Paper page
  76. 10.1517/14728222.11.3.403 · DOI
  77. 10.1038/sj.bjp.0704220 · DOI
  78. 10.1111/j.1471-4159.2005.03380.x · DOI · Paper page
  79. 10.1038/nm1561 · DOI · Paper page
  80. 10.1016/0091-3057(91)90349-7 · DOI · Paper page
  81. 10.1172/JCI200419465 · DOI
  82. 10.1016/j.tem.2006.11.006 · DOI · Paper page
  83. 10.1007/s11060-004-5950-2 · DOI
  84. McHugh D, 2005, Symposium on the Cannabinoids
  85. 10.1182/blood-2002-01-0098 · DOI · Paper page
  86. 10.1038/sj.bjp.0706415 · DOI
  87. 10.1016/0006-2952(95)00109-D · DOI · Paper page
  88. 10.1038/sj.bjp.0707261 · DOI
  89. 10.1038/232579a0 · DOI
  90. 10.1016/S0197-0186(01)00076-6 · DOI
  91. 10.1016/j.neuron.2006.07.006 · DOI · Paper page
  92. 10.1006/bbrc.2002.6635 · DOI
  93. 10.1016/j.pbb.2006.05.018 · DOI
  94. 10.1016/j.bbrc.2005.09.121 · DOI
  95. 10.1016/j.pharmthera.2005.09.009 · DOI
  96. 10.1007/3-7643-7358-X_10 · DOI
  97. 10.1007/s00213-002-1329-2 · DOI
  98. 10.1124/jpet.106.101287 · DOI · Paper page
  99. 10.1016/0163-7258(88)90106-4 · DOI
  100. 10.1038/sj.bjp.0704327 · DOI · Paper page
  101. 10.2174/0929867306666220401124036 · DOI · Paper page
  102. 10.1007/s10681-004-4756-9 · DOI
  103. Pertwee RG, 2004, Cannabinoids, 32
  104. Pertwee RG, 2004, Novel pharmacological targets for cannabinoids, Curr Neuropharmacol, 2, 9, 10.2174/1570159043476927 · doi:10.2174/1570159043476927
  105. Pertwee RG, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 1
  106. 10.1208/aapsj070364 · DOI
  107. 10.1007/3-7643-7358-X_3 · DOI
  108. 10.1038/sj.bjp.0706406 · DOI · Paper page
  109. 10.1007/s12035-007-0005-2 · DOI
  110. Pertwee RG, 2007, GPR55: a new member of the cannabinoid receptor clan?, Br J Pharmacol
  111. 10.1054/plef.2001.0341 · DOI · Paper page
  112. Pertwee RG, 2002, Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens, Eur J Pharmacol, 456, 99, 10.1016/S0014-2999(02)02624-9 · DOI
  113. Pertwee RG, 2007, Signs of cannabinoid CB2 receptor activation by tetrahydrocannabivarin, cannabigerol and cannabidiol, IACM Fourth Conference on Cannabinoids in Medicine
  114. Pertwee RG, 2007, The Cannabinoid Receptors
  115. 10.1038/sj.bjp.0707124 · DOI
  116. 10.1016/S0024-3205(98)00238-0 · DOI
  117. 10.1016/j.neuropharm.2005.11.023 · DOI
  118. 10.1016/S0006-8993(02)03055-X · DOI
  119. 10.1038/sj.bjp.0707003 · DOI
  120. Rakhshan F, 2000, Carrier‐mediated uptake of the endogenous cannabinoid anandamide in RBL‐2H3 cells, J Pharmacol Exp Ther, 292, 960, 10.1016/S0022-3565(24)35376-5 · DOI
  121. 10.1021/jm970126f · DOI
  122. 10.1016/0014-5793(94)00773-X · DOI · Paper page
  123. Robinson L, 2007, Phytocannabinoid induced anorexic behaviour in fasted and non‐fasted mice, IACM Fourth Conference on Cannabinoids in Medicine
  124. Robson P, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 719
  125. 10.1016/S0028-3908(00)00135-0 · DOI · Paper page
  126. 10.1007/s11064-005-6978-1 · DOI · Paper page
  127. 10.1016/j.jneuroim.2004.10.003 · DOI
  128. 10.1111/j.1365-2982.2006.00819.x · DOI
  129. 10.1158/0008-5472.CAN-04-3410 · DOI
  130. 10.1007/s00213-006-0676-9 · DOI
  131. 10.1124/mol.55.1.8 · DOI
  132. 10.1111/j.1471-4159.2006.04346.x · DOI
  133. 10.1016/j.neuropharm.2005.11.008 · DOI
  134. 10.1523/JNEUROSCI.16-24-08057.1996 · DOI · Paper page
  135. 10.1615/CritRevNeurobiol.v15.i2.10 · DOI · Paper page
  136. 10.1124/jpet.102.035618 · DOI
  137. 10.1073/pnas.93.9.3984 · DOI · Paper page
  138. 10.1097/01.mol.0000245257.17764.b2 · DOI
  139. 10.1038/nature03389 · DOI · Paper page
  140. 10.1113/jphysiol.2005.091918 · DOI
  141. 10.1007/3-540-26573-2_11 · DOI · Paper page
  142. 10.1089/jop.2006.22.160 · DOI
  143. 10.1038/sj.bjp.0707133 · DOI · Paper page
  144. 10.1016/j.ejphar.2004.01.023 · DOI
  145. 10.1038/sj.bjp.0706414 · DOI
  146. 10.1097/01.ijg.0000212260.04488.60 · DOI
  147. 10.1136/bjo.2003.032250 · DOI · Paper page
  148. 10.1002/j.1552-4604.1981.tb02625.x · DOI
  149. 10.1152/ajpgi.00113.2003 · DOI
  150. 10.1124/jpet.104.080739 · DOI
  151. Vaughan CW, 2005, Cannabinoids. Handbook of Experimental Pharmacology, 367
  152. 10.1038/37371 · DOI · Paper page
  153. 10.1124/jpet.103.051920 · DOI · Paper page
  154. 10.1016/S0014-2999(01)01243-2 · DOI
  155. 10.1523/JNEUROSCI.23-04-01398.2003 · DOI · Paper page
  156. 10.1038/sj.bjp.0705667 · DOI · Paper page
  157. 10.1248/cpb.38.2317 · DOI
  158. Weston S, 2006, Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity, Proc Br Pharmacol Soc
  159. 10.2174/092986707780363023 · DOI
  160. 10.1038/sj.bjp.0706157 · DOI
  161. Wiley JL, 2001, Novel pyrazole cannabinoids: insights into CB1 receptor recognition and activation, J Pharmacol Exp Ther, 296, 1013, 10.1016/S0022-3565(24)38846-9 · DOI
  162. 10.1016/j.ejphar.2005.01.006 · doi:10.1016/j.ejphar.2005.01.006
  163. 10.1016/j.jdermsci.2006.10.009 · DOI
  164. 10.1021/jm00241a012 · DOI
  165. 10.1189/jlb.0307159 · DOI
  166. 10.1016/j.cancergencyto.2006.06.014 · DOI
  167. 10.1186/1471-2377-6-12 · DOI · Paper page
  168. 10.1046/j.1460-9568.2003.02704.x · DOI · Paper page
  169. 10.1073/pnas.96.10.5780 · DOI · Paper page
  170. 10.1523/JNEUROSCI.22-11-04720.2002 · DOI

Cited by

See all 1,935

Metadata

Authors
Pertwee, R. G.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2008-01
Volume
153
Issue
2
Pages
199-215
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
DOI
10.1038/sj.bjp.0707442
OpenAlex
W2168111104
Cited by
1,935
References
14
FWCI
21.16
Type
journal article
Language
en
Open access
bronze
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 394 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.